Intercept Pharma (ICPT) Completes POISE Enrollment

December 19, 2012 7:12 AM EST Send to a Friend
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept) announced that it has completed enrollment in POISE, its pivotal Phase 3 clinical trial of obeticholic acid (OCA) in primary biliary cirrhosis (PBC). Results from the 12-month double-blind portion of POISE are anticipated to be available in the second quarter of 2014 and, if successful, will be used to seek regulatory approval of OCA, a first-in-class FXR agonist, as a second line treatment in PBC. By enrolling 218 patients at 59 centers in 13 countries, Intercept exceeded its targeted number of patients and completed enrollment in POISE faster than originally projected.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment